Applications Bone

Over six million fractures are sustained in the United States each year and 5-10 percent of those result in nonunion. The current most efficacious treatment to stimulate bone regeneration involves harvesting and transplanting autologous bone chips from the iliac crest of the patient to the injury site.  However, donor site morbidity and pain, lack of structural integrity, and limited graft material volume are significant drawbacks.  Tissue engineering strategies that combine porous biomaterial scaffolds with cells capable of osteogenesis or bioactive proteins have shown promise as effective bone graft substitutes.  However, attempts to culture bone tissue-engineering constructs thicker than 1 mm in vitro have typically resulted in a shell of viable cells and mineralized matrix surrounding a necrotic core due to the absence of a vascular supply.

To improve mass transport and nutrient exchange, 3-D in vitro experiments have shown an increase in cell viability and function and mineral deposition within media perfused cell-seeded scaffolds compared to static controls.  In addition to improved mass transport, perfusion produces flow mediated shear stresses, which have been shown to upregulate osteoblast activity.  BISS is developing bioreactors that can perfuse cell-seeded scaffolds and deliver prescribed pulsatile flow regimes to stimulate mineral growth.  Additionally, these bioreactors facilitate temporal monitoring of mineral deposition via micro-CT scanning.

Physiologic Requirements: BISS OsteoGen Solutions:
Convective Nutrient Transport: Perfusion Capabilities
Uniform Cell Density: Hydrogel Seeding In Situ
Mechanical Stimulation: Mechanical and Wire grip options
Native Physiological Structure and Function: Biomimetic in vitro Environment

 

The OsteoGen architecture provides a physiologic support system that enhances metabolic conditions for cell growth and maintenance in a 3-D environment.  Physiologic parameters are feedback-controlled for culture reproducibility. 

ABOUT BISS TGT

Did you know that BISS TGT has a wide range of products for Tissue Engineering and Regenerative Medicine (TERM) Applications? Our innovative material testing technology is the most comprehensive commercial solution for the TERM market! We are proud to present BISS TGT TERM.

SERVICE & SUPPORT

OUR CUSTOMERS

  • Children's Mercy Hospital and Clinics
  • Cook Biotech
  • Drexel University
  • FDA Center for Devices and Radiological Health
  • Gel-Del Technologies
See Full List

LATEST NEWS

  • The Challenges of Tissue Characterization
    05.27.2014

    The Challenges of Tissue Characterization TERM research is poised to change the way we know health care. This cutting-edge technology demands new tools and solutions that are able to keep up with the development in personalized medicine. Instron® is delivering those solutions.

    More Info
  • BISS featured in THE HINDU
    07.23.2015

    Bangalore Integrated System Solutions (BISS), a leading test equipment manufacturer, prides in not just ‘making in India’ but also in engaging Indian minds and hands for the same. BISS is a Bengaluru-based developer, manufacturer and exporter of digitally-controlled precision test systems for material and component characterisation in industry, R&D and academia.

    More Info
  • As Featured in Quality Magazine
    10.15.2014

    All parties recognize the importance of developing test standards and providing the est possible medical devices, but determining the best methods is a challenge.

    More Info
  • Instron TERM - Video
    10.01.2014

    See the magic of Instron TERM characterize tissue and culture cells.

    More Info
  • Biomedical Advances
    11.19.2014

    Instron TERM's quarterly newsletter is focused on research and product development challenges in the tissue engineering and regenerative medicine field. Topics include new customer applications, new Instron products, and technology innovation updates.

    More Info
  • Instron TERM sponsors ISACB Webinar Series
    01.08.2015

    Register today for the Winter 2015 Webinar on February 5, 2015. "Stem Cell Therapy for Cardiovascular Disease: From Cell to Heart" Robert Deans, PhD & Keith March, MD, PhD

    More Info
Bangalore Integrated System Solutions (P) ltd.
+91 80 28360184 | tgt@biss.in
Copyright © 2015 - 2017 Bangalore Integrated System Solutions (P) ltd. . All Rights Reserved. BISS aquired Tissue Growth Technologies (TGT)